• A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy
Auteur:Di Leo, Angelo; Isola, Jorma; Piette, F; Ejlertsen, Bent; Pritchard, Kathleen; Bartlett, John M S; Desmedt, Christine; Larsimont, Denis; Tanner, M; Mouridsen, Henning; O'Malley, Frances P; Twelves, C.; Cardoso, Fatima; Poole, CJ; Piccart-Gebhart, Martine; Buyse, Marc
Informations sur la publication:Cancer Research Supplement, 2008 SABCS - San Antonio Breast Cancer Symposium, SABCS - San Antonio Breast Cancer Symposium(December 2008: San Antonio, Tx,, USA), Vol. Vol. 69, Issue 2 (Suppl.)
Statut de publication:Publié, 2009-01
Sujet CREF:Cancérologie
Médecine pathologie humaine
Sciences bio-médicales et agricoles